February 16, 2022 -- Terray Therapeutics has closed $60 million in series A financing to advance its novel tNova platform. The financing will be used to advance the company's preclinical pipeline of therapeutics and the company's discovery partnerships.
Terray's chemistry engine operates at a large scale, measuring billions of interactions daily and becoming increasingly precise with each cycle of design and experimentation. Combining these capabilities with unique resynthesis capabilities and broad biology infrastructure, Terray can navigate vast chemical space and deliver therapeutics for previously inaccessible targets, the firm said.
Terray Therapeutics is an emerging biotechnology company led by pioneers and long-time leaders in artificial intelligence (AI), synthetic chemistry, automation, and nanotechnology.
The financing was led by Madrona Venture Group, with participation from a broad syndicate of new and existing investors.
Copyright © 2022 scienceboard.net